Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Myelodysplasias

Low IPSS score and bone marrow hypocellularity in MDS patients predict hematological responses to antithymocyte globulin

Leukemia volume 21, pages 1436–1441 (2007)Cite this article

Abstract

Immunosuppressive therapy has been shown to induce sustained hematological responses in a subset of patients with myelodysplastic syndromes (MDS). In particular, antithymocyte globulin (ATG), a polyclonal immunoglobulin induces hematological responses in up to 60% of MDS patients. We report herein on the results of a retrospective multicenter study on the use of ATG in the treatment of 96 patients with MDS. Patients were evaluated for duration of response to ATG, as well as survival after administration of ATG. The median age of the cohort was 54.7 years (range: 19–75 years), with a median follow-up of 33.8 months (range: 0.8–133 months). A total of 40 patients (42%) achieved a hematological response, of which 30 patients (75%) had a durable hematological response lasting a median duration of 31.5 months (range: 6–92 months). On multivariate analysis, both low International Prognostic Scoring System (IPSS) and bone marrow (BM) hypocellularity were independent predictive factors for improved response to ATG (IPSS Int-2/high: odds ratio (OR) 0.08, P=0.018 and BM normo/hypercellularity: OR 0.49, P=0.012). In addition, IPSS was the sole predictor of overall survival, with Int-2/high risk patients having a significantly poorer survival outcome (OR 0.08, P<0.01). In conclusion, this study identifies BM hypocellularity and a low IPSS as important factors predicting response to ATG.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  1. Mufti GJ, Stevens JR, Oscier DG, Hamblin TJ, Machin D . Myelodysplastic syndromes: a scoring system with prognostic significance. Br J Haematol 1985; 59: 425–433.

    Article  CAS  PubMed  Google Scholar 

  2. Mufti GJ, Figes A, Hamblin TJ, Oscier DG, Copplestone JA . Immunological abnormalities in myelodysplastic syndromes. I. Serum immunoglobulins and autoantibodies. Br J Haematol 1986; 63: 143–147.

    Article  CAS  PubMed  Google Scholar 

  3. Voulgarelis M, Giannouli S, Ritis K, Tzioufas AG . Myelodysplasia-associated autoimmunity: clinical and pathophysiologic concepts. Eur J Clin Invest 2004; 34: 690–700.

    Article  CAS  PubMed  Google Scholar 

  4. Billstrom R, Johansson H, Johansson B, Mitelman F . Immune-mediated complications in patients with myelodysplastic syndromes – clinical and cytogenetic features. Eur J Haematol 1995; 55: 42–48.

    Article  CAS  PubMed  Google Scholar 

  5. Hamblin TJ . Immunological abnormalities in myelodysplastic syndromes. Semin Hematol 1996; 33: 150–162.

    CAS  PubMed  Google Scholar 

  6. Molldrem JJ, Caples M, Mavroudis D, Plante M, Young NS, Barrett AJ . Antithymocyte globulin for patients with myelodysplastic syndrome. Br J Haematol 1997; 99: 699–705.

    Article  CAS  PubMed  Google Scholar 

  7. Killick SB, Mufti G, Cavenagh JD, Mijovic A, Peacock JL, Gordon-Smith EC et al. A pilot study of antithymocyte globulin (ATG) in the treatment of patients with ‘low-risk’ myelodysplasia. Br J Haematol 2003; 120: 679–684.

    Article  CAS  PubMed  Google Scholar 

  8. Sloand EM, Kim S, Fuhrer M, Risitano AM, Nakamura R, Maciejewski JP et al. Fas-mediated apoptosis is important in regulating cell replication and death in trisomy 8 hematopoietic cells but not in cells with other cytogenetic abnormalities. Blood 2002; 100: 4427–4432.

    Article  CAS  PubMed  Google Scholar 

  9. Melenhorst JJ, Eniafe R, Follmann D, Nakamura R, Kirby M, Barrett AJ . Molecular and flow cytometric characterization of the CD4 and CD8 T-cell repertoire in patients with myelodysplastic syndrome. Br J Haematol 2002; 119: 97–105.

    Article  CAS  PubMed  Google Scholar 

  10. Kochenderfer JN, Kobayashi S, Wieder ED, Su C, Molldrem JJ . Loss of T-lymphocyte clonal dominance in patients with myelodysplastic syndrome responsive to immunosuppression. Blood 2002; 100: 3639–3645.

    Article  CAS  PubMed  Google Scholar 

  11. Molldrem JJ, Jiang YZ, Stetler-Stevenson M, Mavroudis D, Hensel N, Barrett AJ . Haematological response of patients with myelodysplastic syndrome to antithymocyte globulin is associated with a loss of lymphocyte-mediated inhibition of CFU-GM and alterations in T-cell receptor Vbeta profiles. Br J Haematol 1998; 102: 1314–1322.

    Article  CAS  PubMed  Google Scholar 

  12. Barrett J, Saunthararajah Y, Molldrem J . Myelodysplastic syndrome and aplastic anemia: distinct entities or diseases linked by a common pathophysiology? Semin Hematol 2000; 37: 15–29.

    Article  CAS  PubMed  Google Scholar 

  13. Stadler M, Germing U, Kliche KO, Josten KM, Kuse R, Hofmann WK et al. A prospective, randomised, phase II study of horse antithymocyte globulin vs rabbit antithymocyte globulin as immune-modulating therapy in patients with low-risk myelodysplastic syndromes. Leukemia 2004; 18: 460–465.

    Article  CAS  PubMed  Google Scholar 

  14. Yazji S, Giles FJ, Tsimberidou AM, Estey EH, Kantarjian HM, O'Brien SA et al. Antithymocyte globulin (ATG)-based therapy in patients with myelodysplastic syndromes. Leukemia 2003; 17: 2101–2106.

    Article  CAS  PubMed  Google Scholar 

  15. Saunthararajah Y, Nakamura R, Nam JM, Robyn J, Loberiza F, Maciejewski JP et al. HLA-DR15 (DR2) is overrepresented in myelodysplastic syndrome and aplastic anemia and predicts a response to immunosuppression in myelodysplastic syndrome. Blood 2002; 100: 1570–1574.

    CAS  PubMed  Google Scholar 

  16. Broliden PA, Dahl IM, Hast R, Johansson B, Juvonen E, Kjeldsen L et al. Antithymocyte globulin and cyclosporine A as combination therapy for low-risk non-sideroblastic myelodysplastic syndromes. Haematologica 2006; 91: 667–670.

    CAS  PubMed  Google Scholar 

  17. Molldrem JJ, Leifer E, Bahceci E, Saunthararajah Y, Rivera M, Dunbar C et al. Antithymocyte globulin for treatment of the bone marrow failure associated with myelodysplastic syndromes. Ann Intern Med 2002; 137: 156–163.

    Article  PubMed  Google Scholar 

  18. Michallet MC, Preville X, Flacher M, Fournel S, Genestier L, Revillard JP . Functional antibodies to leukocyte adhesion molecules in antithymocyte globulins. Transplantation 2003; 75: 657–662.

    Article  CAS  PubMed  Google Scholar 

  19. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982; 51: 189–199.

    Article  CAS  PubMed  Google Scholar 

  20. Cheson BD, Bennett JM, Kantarjian H, Pinto A, Schiffer CA, Nimer SD et al. Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood 2000; 96: 3671–3674.

    CAS  PubMed  Google Scholar 

  21. Aivado M, Rong A, Stadler M, Germing U, Giagounidis A, Strupp C et al. Favourable response to antithymocyte or antilymphocyte globulin in low-risk myelodysplastic syndrome patients with a ‘non-clonal’ pattern of X-chromosome inactivation in bone marrow cells. Eur J Haematol 2002; 68: 210–216.

    Article  CAS  PubMed  Google Scholar 

  22. Saunthararajah Y, Nakamura R, Wesley R, Wang QJ, Barrett AJ . A simple method to predict response to immunosuppressive therapy in patients with myelodysplastic syndrome. Blood 2003; 102: 3025–3027.

    Article  CAS  PubMed  Google Scholar 

  23. Sloand EM, Mainwaring L, Fuhrer M, Ramkissoon S, Risitano AM, Keyvanafar K et al. Preferential suppression of trisomy 8 compared with normal hematopoietic cell growth by autologous lymphocytes in patients with trisomy 8 myelodysplastic syndrome. Blood 2005; 106: 841–851.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Martinez-Jaramillo G, Flores-Figueroa E, Sanchez-Valle E, Gutierrez-Espindola G, Gomez-Morales E, Montesinos JJ et al. Comparative analysis of the in vitro proliferation and expansion of hematopoietic progenitors from patients with aplastic anemia and myelodysplasia. Leuk Res 2002; 26: 955–963.

    Article  CAS  PubMed  Google Scholar 

  25. Young NS, Maciejewski J . The pathophysiology of acquired aplastic anemia. N Engl J Med 1997; 336: 1365–1372.

    Article  CAS  PubMed  Google Scholar 

  26. Nakao S, Takami A, Sugimori N, Ueda M, Shiobara S, Matsuda T et al. Response to immunosuppressive therapy and an HLA-DRB1 allele in patients with aplastic anaemia: HLA-DRB1*1501 does not predict response to antithymocyte globulin. Br J Haematol 1996; 92: 155–158.

    Article  CAS  PubMed  Google Scholar 

  27. Nimer SD, Ireland P, Meshkinpour A, Frane M . An increased HLA DR2 frequency is seen in aplastic anemia patients. Blood 1994; 84: 923–927.

    CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We are grateful to Nora Donaldson for her statistical advice.

Author information

Authors and Affiliations

  1. Department of Haematological Medicine, Kings College London, Kings College Hospital, London, UK

    Z Y Lim & G J Mufti

  2. Department of Haematology, Royal Bournemouth NHS Foundation Trust, Bournemouth, UK

    S Killick

  3. Department of Hematology, Oncology, and Clinical Immunology, Heinrich-Heine-University, Düsseldorf, Germany

    U Germing

  4. Department of Haematology, St Batholomew's and The Royal London Hospitals, London, UK

    J Cavenagh

  5. Department of Haematology, Aberdeen Royal Infirmary, Aberdeen, UK

    D Culligan

  6. Dipartimento di Emato-Oncologia, Ospedale San Martino, Genova, Italy

    A Bacigalupo

  7. Department of Haematology, St George's Hosptal, London, UK

    J Marsh

Authors
  1. Z Y Lim
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S Killick
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. U Germing
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. J Cavenagh
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. D Culligan
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. A Bacigalupo
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. J Marsh
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. G J Mufti
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to G J Mufti.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lim, Z., Killick, S., Germing, U. et al. Low IPSS score and bone marrow hypocellularity in MDS patients predict hematological responses to antithymocyte globulin. Leukemia 21, 1436–1441 (2007). https://doi.org/10.1038/sj.leu.2404747

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.leu.2404747

Keywords

This article is cited by

Search

Advanced search

Quick links